[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583522":3},{"organization":4,"armGroups":7,"interventions":34,"overallOfficials":10,"centralContacts":38,"locations":44,"responsibleParty":59,"collaborators":10,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":10,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":10,"maxAge":10,"enrollmentInfo":71,"targetDuration":10,"studyType":74,"phases":10,"briefSummary":75,"conditions":76,"keywords":80,"overallStatus":47,"whyStopped":10,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8,13,16,19,22,25,28,31],{"label":9,"type":10,"description":10,"interventionNames":11},"First-line Trastuzumab Deruxtecan → Second-line Sacituzumab Govitecan",null,[12],"Other: Non-intervention research",{"label":14,"type":10,"description":10,"interventionNames":15},"First-line Sacituzumab Govitecan → Second-line Trastuzumab Deruxtecan",[12],{"label":17,"type":10,"description":10,"interventionNames":18},"First-line RC48 → Second-line Trastuzumab Deruxtecan",[12],{"label":20,"type":10,"description":10,"interventionNames":21},"First-line Trastuzumab Deruxtecan → Second-line RC48",[12],{"label":23,"type":10,"description":10,"interventionNames":24},"First-line SKB264 → Second-line Trastuzumab Deruxtecan",[12],{"label":26,"type":10,"description":10,"interventionNames":27},"First-line Trastuzumab Emtansine → Second-line TQB2102",[12],{"label":29,"type":10,"description":10,"interventionNames":30},"First-line TQB2102 → Second-line Trastuzumab Deruxtecan",[12],{"label":32,"type":10,"description":10,"interventionNames":33},"First-line RC48 → Second-line TQB2102",[12],[35],{"type":6,"name":36,"description":36,"armGroupLabels":37,"otherNames":10},"Non-intervention research",[32,17,23,14,29,20,9,26],[39],{"name":40,"role":41,"phone":42,"phoneExt":10,"email":43},"Yang Yalan, Bachelor","CONTACT","+8613826282096","yangylan7@mail2.sysu.edu.cn",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":10},"Sun yat-sen University Cancer","RECRUITING","Guangzhou","Guangdong","510060","China","CN",{"type":54,"coordinates":55},"Point",[56,57],113.25,23.11667,{"lat":57,"lon":56},{"type":60,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Yalan Yang","Clinical Investigator","100583522","analysis-of-exploring-optimized-sequential-treatment-strategies-of-antibody-drug-conjugates-adcs-in-her2-low-expressing-breast-cancer-100583522",false,"NCT06877416","Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer","A Multi-center, Retrospective, Study on Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer","Inclusion Criteria:\n\n* Diagnosed with HER2-low breast cancer, defined as immunohistochemistry (IHC) score of 1+ or IHC score of 2+ with negative in situ hybridization (FISH-negative)\n* Received sequential administration of two or more ADCs\n* Complete data for patient's character, laboratory and imaging test, treatment and follow-up are available.\n\nExclusion Criteria:\n\n* Concomitant with other tumor components at the time of diagnosis;\n* Have a history of any other malignant tumors;\n* Lack of complete data","ALL",{"count":72,"type":73},700,"ESTIMATED","OBSERVATIONAL","This study retrospectively analyzes the clinical data of HER2-low breast cancer (IHC 1+\u002F2+ and FISH-negative) patients treated with sequential antibody-drug conjugates (ADCs). Key variables include patient demographics, tumor characteristics, ADC regimens (e.g., trastuzumab deruxtecan, sacituzumab govitecan), treatment sequencing, survival outcomes, and safety profiles. Genomic data (e.g., HER2 expression dynamics, TROP2 levels) are integrated to explore resistance mechanisms and prognostic biomarkers.mechanisms.\n\nThis study aims to investigate the efficacy of different ADC sequential regimens in HER2-low breast cancer patients.",[77,78,79],"Antibody-drug Conjugates","HER2-low Breast Cancer","Breast Neoplasms",[81,78,82],"Antibody-drug conjugates","Retrospective Studies","2025-03-17",{"date":85,"type":86},"2025-03-20","ACTUAL",{"date":88,"type":86},"2020-01-01",{"date":90,"type":73},"2026-01",{"name":5,"class":6},1]